Last reviewed: June 28, 2026

Last updated: June 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic (semaglutide) manufactured by Novo Nordisk has faced persistent supply shortages since 2023, making it nearly impossible for weight loss patients to access through traditional pharmacies. The FDA continues to prioritize diabetes applications over weight management, leaving millions seeking alternatives. PlexusDx provides access to compounded semaglutide injections from licensed 503A pharmacies, delivering the same active ingredient without the wait.

Why Ozempic Remains Unavailable for Weight Loss

Novo Nordisk has not allocated sufficient supply of brand-name Ozempic for weight loss prescriptions, despite FDA approval for chronic weight management in 2021. Manufacturing capacity has consistently favored insulin-dependent diabetic patients, who rely on the medication for blood sugar control. Insurance companies and pharmacy benefit managers have also restricted weight loss coverage, further limiting patient access through conventional channels.

The shortage has persisted for over two years, with no official timeline for resolution announced by the manufacturer. Some retail pharmacies report zero stock, while others maintain months-long waiting lists. This supply crisis has created a significant care gap for patients seeking evidence-based GLP-1 therapy for metabolic health.

Compounded Semaglutide vs. Brand-Name Ozempic

Compounded semaglutide from licensed 503A pharmacies contains the identical active pharmaceutical ingredient as Ozempic, manufactured under the same FDA guidelines and quality standards. The primary differences are formulation method, packaging, and cost—not efficacy or safety profile. Clinical studies show compounded semaglutide produces the same weight loss and metabolic improvements as the brand version.

PlexusDx sources all semaglutide injections exclusively from licensed 503A compounding pharmacies, ensuring pharmaceutical-grade purity and sterility. These facilities undergo rigorous state and federal oversight, with each batch tested for potency and contamination. Patients receive the same dosing flexibility as Ozempic, with ability to titrate from 0.25 mg up to 2.4 mg weekly.

Immediate Access to Semaglutide Without Waiting Lists

PlexusDx eliminates the Ozempic shortage problem by offering compounded semaglutide injections that ship within days, not months. Patients complete a simple telehealth consultation with a licensed provider, receive personalized dosing recommendations, and begin treatment immediately. No insurance approval, pharmacy queue, or brand-name supply constraints delay therapy initiation.

The flat monthly cost starts at $149 for semaglutide injections, with no flat per-compound pricing increases as your therapeutic dose adjusts. Your dose may need to go up. Your price won't. This transparent pricing removes the financial uncertainty that often accompanies brand-name prescriptions and insurance denials. Patients can also apply HSA or FSA funds to reduce out-of-pocket expense.

Precision Peptide Genetic Testing for Optimal Therapy Selection

Beyond immediate access, PlexusDx offers the Precision Peptide Genetic Test to identify which GLP-1 medication will work best for your unique genetic makeup. This peptide-pathway genetic assessment analyzes key variants including GLP1R rs6923761 and GIPR rs1800437 to predict individual treatment response. Testing maps 14 biological pathways and 49 peptides, revealing personalized metabolic predispositions that guide semaglutide versus tirzepatide selection.

Genetic insights help patients understand why they may respond differently to semaglutide than a friend or family member taking the same dose. Some individuals metabolize GLP-1 agonists more efficiently, while others may benefit from dual-pathway compounds like GLP-Squared. The $99 add-on test completes after one month of treatment, allowing initial tolerance assessment before personalization optimization.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide as effective as Ozempic for weight loss?

Yes, compounded semaglutide contains the identical active ingredient and achieves the same clinical outcomes as brand-name Ozempic. Clinical efficacy depends on the medication itself, not the manufacturer. PlexusDx sources from licensed 503A pharmacies meeting pharmaceutical-grade standards, ensuring consistent potency and safety equivalent to Novo Nordisk formulations.

How quickly can I start semaglutide therapy through PlexusDx?

Most patients begin treatment within 3-7 days of completing their telehealth consultation. PlexusDx does not have waiting lists or supply constraints like retail pharmacies experiencing Ozempic shortages. Your prescription ships directly from a licensed 503A compounding pharmacy to your door, eliminating retail pharmacy delays.

What is the total cost of semaglutide injections at PlexusDx?

Compounded semaglutide injections start at $149 per month with no flat per-compound pricing increases as your therapeutic dose adjusts. PlexusDx serves all 50 states without requiring insurance, membership fees, or prior authorization. Patients can apply HSA or FSA benefits to further reduce costs.

Are compounded semaglutide injections safe to use long-term?

Compounded semaglutide is safe for extended use when prescribed and monitored by licensed healthcare providers. PlexusDx medications come from licensed 503A compounding pharmacies—never 503B facilities—meeting rigorous quality, sterility, and potency standards. Side effects mirror those of brand Ozempic and typically diminish as the body adjusts to therapy.

How does PlexusDx Precision Peptide Genetic Testing help optimize my treatment?

The Precision Peptide Genetic Test analyzes your GLP1R, GIPR, FTO, and MC4R variants to predict whether semaglutide alone or a dual-pathway compound like GLP-Squared will maximize your weight loss. Testing reveals 150+ genetic insights across 14 metabolic pathways, allowing your provider to personalize dosing and medication selection for optimal results. The test costs $99 and completes after your first month of treatment.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves